Jul 31, 2023
FDA Approves First-Line Enzalutamide/Talazoparib Combo in Prostate Cancer
Posted by Omuterema Akhahenda in categories: biotech/medical, genetics
The U.S Food and Drug Administration (FDA) has approved a new drug combination for men with metastatic, castration-resistant prostate cancer (mCRPC) and certain DNA repair gene mutations, widening treatment options for this large patient population.
The androgen-receptor inhibitor enzalutamide plus the PARP inhibitor talazoparib can now be used as first-line treatment for mCRPC patients who have homologous recombination repair (HRR) gene alterations.
#MetastaticProstateCancer.
Continue reading “FDA Approves First-Line Enzalutamide/Talazoparib Combo in Prostate Cancer” »